Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
paper
Cited
Public
Unavailable
- Authors
- Ramesh, Divya; Ross, Gracious R; Schlosburg, Joel E; Owens, Robert A; Abdullah, Rehab A; Kinsey, Steven G; Long, Jonathan Z; Nomura, Daniel K; Sim-Selley, Laura J; Cravatt, Benjamin F; Akbarali, Hamid I; Lichtman, Aron H
- Year
- 2011
- Journal
- The Journal of pharmacology and experimental therapeutics
- PMID
- 21719468
- DOI
- 10.1124/jpet.111.181370
- PMCID
- PMC3186294
Ξ(9)-Tetrahydrocannbinol (THC), the primary active constituent of Cannabis sativa, has long been known to reduce opioid withdrawal symptoms. Although THC produces most of its pharmacological actions through the activation of CB(1) and CB(2) cannabinoid receptors, the role these receptors play in reducing the variety of opioid withdrawal symptoms remains unknown. The endogenous cannabinoids, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), activate both cannabinoid receptors but are rapidly metabolized by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. The objective of this study was to test whether increasing AEA or 2-AG, via inhibition of their respective hydrolytic enzymes, reduces naloxone-precipitated morphine withdrawal symptoms in in vivo and in vitro models of opioid dependence. Morphine-dependent mice challenged with naloxone reliably displayed a profound withdrawal syndrome, consisting of jumping, paw tremors, diarrhea, and weight loss. THC and the MAGL inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) dose dependently reduced the intensity of most measures through the activation of CB(1) receptors. JZL184 also attenuated spontaneous withdrawal signs in morphine-dependent mice. The FAAH inhibitor N-(pyridin-3-yl)-4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzyl)-piperdine-1-carboxamide (PF-3845) reduced the intensity of naloxone-precipitated jumps and paw flutters through the activation of CB(1) receptors but did not ameliorate incidence of diarrhea or weight loss. In the final series of experiments, we investigated whether JZL184 or PF-3845 would attenuate naloxone-precipitated contractions in morphine-dependent ilea. Both enzyme inhibitors attenuated the intensity of naloxone-induced contractions, although this model does not account mechanistically for the autonomic withdrawal responses (i.e., diarrhea) observed in vivo. These results indicate that endocannabinoid catabolic enzymes are promising targets to treat opioid dependence.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders. | Maddox CJ et al. | β | 2026 | β |
| Fentanyl exposure alters rat CB1 receptor expression in the insula, nucleus accumbens and substantia nigra. | Gacso Z et al. | β | 2025 | β |
| Investigation of the Inhibitory Effect of Naringin on the Development of Morphine Physical Dependency in Male Rats. | Alifarsangi A et al. | β | 2025 | β |
| Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward | Woodward TJ et al. | β | 2025 | β |
| Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward. | Woodward TJ et al. | β | 2025 | β |
| The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review. | Powell A et al. | β | 2025 | β |
| Cannabis donation as a harm reduction strategy: a case study. | Duhart Clarke SE et al. | β | 2024 | β |
| Elucidating the molecular symphony: unweaving the transcriptional & epigenetic pathways underlying neuroplasticity in opioid dependence and withdrawal. | Wani SN et al. | β | 2024 | β |
| Endocannabinoid agonist 2-arachidonoylglycerol differentially alters diurnal activity and sleep during fentanyl withdrawal in male and female mice. | Gamble MC et al. | β | 2024 | β |
| Endocannabinoids and related lipids linked to social exclusion in individuals with chronic non-medical prescription opioid use. | Kroll SL et al. | β | 2024 | β |
| Anxiety associated with palatable food withdrawal is reversed by the selective FAAH inhibitor PF-3845: A regional analysis of the contribution of endocannabinoid signaling machinery. | de Ceglia M et al. | β | 2023 | β |
| Dysregulation of the endogenous cannabinoid system following opioid exposure. | Mohammad Aghaei A et al. | β | 2023 | β |
| Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS. | Kouchaeknejad A et al. | β | 2023 | β |
| Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. | De Aquino JP et al. | β | 2022 | β |
| The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. | Dodu JC et al. | β | 2022 | β |
| Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors. | Laksmidewi AAAP et al. | β | 2021 | β |
| Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance. | Everett TJ et al. | β | 2021 | β |
| Fecal microbiota transplantation and antibiotic treatment attenuate naloxone-precipitated opioid withdrawal in morphine-dependent mice. | Thomaz AC et al. | β | 2021 | β |
| Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. | Rock EM et al. | β | 2020 | β |
| Conformational gating, dynamics and allostery in human monoacylglycerol lipase. | Tyukhtenko S et al. | β | 2020 | β |
| Druggable Targets in Endocannabinoid Signaling. | Gregus AM et al. | β | 2020 | β |
| Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice. | Xu W et al. | β | 2020 | β |
| FAAH levels and its genetic polymorphism association with susceptibility to methamphetamine dependence. | Zhang W et al. | β | 2020 | β |
| Positive Allosteric Modulation of CB<sub>1</sub> Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. | Slivicki RA et al. | β | 2020 | β |
| The cannabinoid CB<sub>2</sub> receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. | Iyer V et al. | β | 2020 | β |
| The role of catecholamines in modulating responses to stress: Sex-specific patterns, implications, and therapeutic potential for post-traumatic stress disorder and opiate withdrawal. | Ross JA et al. | β | 2020 | β |
| Endocannabinoid System and Alcohol Abuse Disorders. | Basavarajappa BS | β | 2019 | β |
| Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats. | Petrie GN et al. | β | 2019 | β |
| Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. | Galaj E et al. | β | 2019 | β |
| 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain. | Baggelaar MP et al. | β | 2018 | β |
| Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase. | Tyukhtenko S et al. | β | 2018 | β |
| Loren Parsons' contribution to addiction neurobiology. | De Luca MA et al. | β | 2018 | β |
| Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. | Curry ZA et al. | β | 2018 | β |
| Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. | Panlilio LV et al. | β | 2018 | β |
| Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms. | Soderstrom K et al. | β | 2017 | β |
| Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors. | Granchi C et al. | β | 2017 | β |
| Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. | Marcus DJ et al. | β | 2017 | β |
| Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. | Grabner GF et al. | β | 2017 | β |
| The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. | Wilkerson JL et al. | β | 2017 | β |
| The endocannabinoid system as a target for addiction treatment: Trials and tribulations. | Sloan ME et al. | β | 2017 | β |
| 4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. | Granchi C et al. | β | 2016 | β |
| Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice. | Owens RA et al. | β | 2016 | β |
| Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats. | Wills KL et al. | β | 2016 | β |
| Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer. | Cajanus K et al. | β | 2016 | β |
| Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature. | Wills KL et al. | β | 2016 | β |
| Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex. | Sticht MA et al. | β | 2016 | β |
| Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. | Lofwall MR et al. | β | 2016 | β |
| The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence. | Alavi MS et al. | β | 2016 | β |
| The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. | Wilkerson JL et al. | β | 2016 | β |
| Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. | Gamage TF et al. | β | 2015 | β |
| Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus. | Parker LA et al. | β | 2015 | β |
| Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice. | Bhalla S et al. | β | 2015 | β |
| Experiences of Kratom Users: A Qualitative Analysis. | Swogger MT et al. | β | 2015 | β |
| Genetic Manipulation of the Endocannabinoid System. | Zimmer A | β | 2015 | β |
| Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. | Bashashati M et al. | β | 2015 | β |
| Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. | Muldoon PP et al. | β | 2015 | β |
| Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. | Befort K | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice. | Ignatowska-Jankowska B et al. | β | 2015 | β |
| The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view. | Fowler CJ | β | 2015 | β |
| Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. | Limebeer CL et al. | β | 2014 | β |
| Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. | Davis MP | β | 2014 | β |
| Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. | Sexton M et al. | β | 2014 | β |
| CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. | Wills KL et al. | β | 2014 | β |
| Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. | Kohnz RA et al. | β | 2014 | β |
| Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. | Pertwee RG | β | 2014 | β |
| Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell. | De Luca MA et al. | β | 2014 | β |
| In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. | Ignatowska-Jankowska BM et al. | β | 2014 | β |
| Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone? | Oleson EB et al. | β | 2014 | β |
| Chemical probes of endocannabinoid metabolism. | Blankman JL et al. | β | 2013 | β |
| Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. | Ramesh D et al. | β | 2013 | β |
| Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. | Fichna J et al. | β | 2013 | β |
| Endocannabinoid system and drug addiction: new insights from mutant mice approaches. | Maldonado R et al. | β | 2013 | β |
| Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. | Panlilio LV et al. | β | 2013 | β |
| Medications development for opioid abuse. | Negus SS et al. | β | 2013 | β |
| Therapeutic potential of monoacylglycerol lipase inhibitors. | Mulvihill MM et al. | β | 2013 | β |
| Using dopamine research to generate rational cannabinoid drug policy. | Loewinger GC et al. | β | 2013 | β |
| A comparison of the effects of digoxin, ouabain and milrinone on naloxone-precipitated withdrawal syndrome in mice. | Bai YL et al. | β | 2012 | β |
| AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. | Seely KA et al. | β | 2012 | β |
| Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. | Luchicchi A et al. | β | 2012 | β |
| Endogenous opiates and behavior: 2011. | Bodnar RJ | β | 2012 | β |
| Monoacylglycerol lipase - a target for drug development? | Fowler CJ | β | 2012 | β |
| Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. | Ritter JK et al. | β | 2012 | β |